While a comprehensive cure-all to these neurological conditions is unlikely, scientists are making headway into understanding their fundamental characteristics with the hope of preventing or ...

Neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS (amyotrophic lateral sclerosis) are debilitating conditions ...

A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...

The EAP trial, funded by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) 1-3, will evaluate the safety ... of neurodegenerative diseases such as ALS (amyotrophic ...

George Magrath, M.D., Chief Executive Officer of Opus Genetics ... uses an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to the outer retina. OPGx-LCA5 is ...

The EAP trial, funded by the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS)1-3, will evaluate ... such as ALS (amyotrophic lateral sclerosis), progressive MS ...

Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1.25 billion by 2032 as treatment innovations accelerate. US,.

Credit: Getty Images In a phase 3, open-label safety extension study, researchers evaluated the safety of oral edaravone in patients with amyotrophic lateral sclerosis over 96 weeks. Oral ...

Background: Lateral trunk flexion (LTF ... Fifty-eight patients with PD (mean age: 76.1 ± 8.7 years; disease duration: 9.2 years) participated in this study. The PD diagnosis process followed the ...

The Blue Devils led by 14 with about 8 1/2 minutes left before seeing Houston ... SAN ANTONIO (AP) — Duke star Cooper Flagg is The Associated Press men's college basketball national player ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on Saturday won a prestigious Breakthrough Prize, the award nicknamed the "Oscars of ...